Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
暂无分享,去创建一个
G. Watts | B. Nordestgaard | G. Kolovou | D. Mikhailidis | S. Mora | P. Pérez-Martínez | J. López-Miranda | T. Ooi | N. Tentolouris | A. Tybjærg‐Hansen | N. Katsiki | H. Bilianou | G. Panotopoulos
[1] Deepak L. Bhatt,et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.
[2] M. Eriksson,et al. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients , 2018, Journal of the American Heart Association.
[3] E. Nozaki,et al. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease , 2018, Heart and Vessels.
[4] J. Ordovás,et al. Long-term consumption of a Mediterranean diet improves postprandial lipemia in patients with type 2 diabetes: the Cordioprev randomized trial. , 2018, The American journal of clinical nutrition.
[5] J. Pais de Barros,et al. Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[6] S. Yamashita,et al. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. , 2018, Journal of clinical lipidology.
[7] P. Barter,et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial , 2018, Circulation.
[8] F. Boeno,et al. Acute and residual effects of aerobic exercise on fructose-induced postprandial lipemia on lean male subjects , 2018, European Journal of Nutrition.
[9] Omar Yaxmehen Bello-Chavolla,et al. Identification of a threshold to discriminate fasting hypertriglyceridemia with postprandial values , 2018, Lipids in Health and Disease.
[10] K. Reynolds,et al. Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol , 2018, The Journal of clinical endocrinology and metabolism.
[11] N. Rifai,et al. Tietz textbook of clinical chemistry and molecular diagnostics , 2018 .
[12] A. Orem,et al. Relationship between postprandial lipemia and atherogenic factors in healthy subjects by considering gender differences. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[13] C. Álvarez,et al. Exercise and postprandial lipemia: effects on vascular health in inactive adults , 2018, Lipids in Health and Disease.
[14] M. Haub,et al. Postprandial Metabolic Responses Differ by Age Group and Physical Activity Level , 2018, The journal of nutrition, health & aging.
[15] B. Nordestgaard,et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals , 2018, European heart journal.
[16] M. Kanthimathi,et al. The amount and types of fatty acids acutely affect insulin, glycemic and gastrointestinal peptide responses but not satiety in metabolic syndrome subjects , 2018, European Journal of Nutrition.
[17] F. Chen,et al. Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .
[18] B. Nordestgaard. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. , 2017, Journal of the American College of Cardiology.
[19] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[20] G. Kolovou,et al. Erratum to: Assessment of the Validity and Reproducibility of a Novel Standardized Test Meal for the Study of Postprandial Triacylglycerol Concentrations , 2017, Lipids.
[21] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[22] C. Mantzoros,et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. , 2017, Metabolism: clinical and experimental.
[23] S. Yamashita,et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. , 2017, Atherosclerosis.
[24] Laurel A. Littlefield,et al. The effect of exercise intensity and excess postexercise oxygen consumption on postprandial blood lipids in physically inactive men. , 2017, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.
[25] G. Kolovou,et al. Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus. , 2017, Current vascular pharmacology.
[26] Tanya M. Teslovich,et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.
[27] Amnon Schlegel,et al. Role of Intestinal LXRα in Regulating Post-prandial Lipid Excursion and Diet-Induced Hypercholesterolemia and Hepatic Lipid Accumulation , 2017, Front. Physiol..
[28] J. Tune,et al. Cardiovascular consequences of metabolic syndrome. , 2017, Translational research : the journal of laboratory and clinical medicine.
[29] Eliot A Brinton,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[30] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[31] Lawrence A Leiter,et al. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes , 2017, JAMA cardiology.
[32] J. Danesh,et al. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. , 2017, Journal of the American College of Cardiology.
[33] P. Ponikowski,et al. Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients , 2017, The New England journal of medicine.
[34] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[35] Daniel R. Lavage,et al. Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease , 2017, JAMA.
[36] M. Scartezini,et al. Positioning about the Flexibility of Fasting for Lipid Profiling , 2017, Arquivos brasileiros de cardiologia.
[37] W. Wahli,et al. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome , 2017, Expert opinion on therapeutic targets.
[38] Michael E. Cobble,et al. Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women , 2017, Journal of the Endocrine Society.
[39] A. Khvorova. Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. , 2017, The New England journal of medicine.
[40] M. Mancini,et al. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release , 2017, Expert opinion on drug safety.
[41] S. Yamashita,et al. Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study , 2017, Journal of atherosclerosis and thrombosis.
[42] G. Li Volti,et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study , 2016, Cardiovascular Diabetology.
[43] J. Car,et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. , 2016, Atherosclerosis. Supplements.
[44] M. Phipps,et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.
[45] G. Francis,et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. , 2016, The Canadian journal of cardiology.
[46] V. Athyros,et al. Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? , 2016, Current vascular pharmacology.
[47] K. Bibbins-Domingo. Colorectal Cancer Screening Recommendations-Reply. , 2016, JAMA.
[48] A. Hoes,et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.
[49] R. Giugliano,et al. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe , 2016, Digestive Diseases and Sciences.
[50] J. Borén,et al. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity , 2016, Current opinion in lipidology.
[51] Y. Ahn,et al. Effect of fixed‐dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‐ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe) , 2016, Cardiovascular therapeutics.
[52] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[53] G. Kolovou,et al. Cigarette smoking/cessation and metabolic syndrome , 2016 .
[54] I. Borecki,et al. Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. , 2016, Journal of clinical lipidology.
[55] S. R. Ferreira,et al. Impact of the Content of Fatty Acids of Oral Fat Tolerance Tests on Postprandial Triglyceridemia: Systematic Review and Meta-Analysis , 2016, Nutrients.
[56] M. Monami,et al. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials , 2016, Acta Diabetologica.
[57] C. Mantzoros,et al. Non-alcoholic fatty liver disease and dyslipidemia: An update. , 2016, Metabolism: clinical and experimental.
[58] A. Lonardo,et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. , 2016, Metabolism: clinical and experimental.
[59] D. Mikhailidis,et al. Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions , 2016, Current medical research and opinion.
[60] S. Cremers,et al. Impaired postprandial lipemic response in chronic kidney disease. , 2016, Kidney international.
[61] D. Mikhailidis,et al. Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed? , 2016, Current vascular pharmacology.
[62] J. Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[63] Darshak M Sanghavi,et al. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. , 2016, JAMA cardiology.
[64] B. Capaldo,et al. Effects of Sleeve Gastrectomy and Gastric Bypass on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients: a 2-Year Follow-up , 2016, Obesity Surgery.
[65] J. Borén,et al. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? , 2016, Current Cardiology Reports.
[66] P. Toth. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease , 2016, Vascular health and risk management.
[67] D. Gudbjartsson,et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.
[68] P. McFarlane,et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.
[69] F. Kronenberg,et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.
[70] M. Malagón,et al. Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study , 2016, Cardiovascular Diabetology.
[71] R. DeFronzo,et al. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study , 2016, Diabetes Care.
[72] P. Pérez-Martínez,et al. Mediterranean Diet and Cardiovascular Risk: Beyond Traditional Risk Factors , 2016, Critical reviews in food science and nutrition.
[73] Hiroshi Ito,et al. Postprandial hyperlipidemia as a potential residual risk factor. , 2016, Journal of cardiology.
[74] B. Nordestgaard,et al. Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. , 2016, Clinical chemistry.
[75] S. Boutcher,et al. Effect of acute interval sprinting exercise on postprandial lipemia of sedentary young men , 2016, Journal of exercise nutrition & biochemistry.
[76] E. Bugianesi,et al. Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load , 2016, International journal of molecular sciences.
[77] A. Thackray,et al. High-Intensity Running and Energy Restriction Reduce Postprandial Lipemia in Girls. , 2016, Medicine and science in sports and exercise.
[78] A. Tenenbaum,et al. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two–Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry , 2016, Circulation. Cardiovascular quality and outcomes.
[79] Christian Sonesson,et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis , 2016, Cardiovascular Diabetology.
[80] B. Nordestgaard. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.
[81] Rachel M. Brown,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.
[82] K. Parhofer,et al. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[83] A. Tenenbaum,et al. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial , 2016, Cardiovascular Diabetology.
[84] D. Fuchs,et al. Diet Versus Exercise in Weight Loss and Maintenance: Focus on Tryptophan , 2016, International journal of tryptophan research : IJTR.
[85] D. Kiortsis,et al. Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug? , 2015, Current vascular pharmacology.
[86] P. Ridker,et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2015, Circulation.
[87] I. Ford,et al. Long-term follow-up of lipid-lowering trials , 2015, Current opinion in lipidology.
[88] R. Hegele,et al. Novel therapeutics in hypertriglyceridemia , 2015, Current opinion in lipidology.
[89] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[90] J. Mckenney,et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. , 2015, Journal of clinical lipidology.
[91] I. Borecki,et al. Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). , 2015, Metabolism: clinical and experimental.
[92] P. Ridker,et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial , 2015 .
[93] M. Kanthimathi,et al. Effects of amount and type of dietary fats on postprandial lipemia and thrombogenic markers in individuals with metabolic syndrome. , 2015, Atherosclerosis.
[94] Olga V. Demler,et al. Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. , 2015, Clinical chemistry.
[95] P. O'Malley,et al. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline , 2015, Annals of Internal Medicine.
[96] D. Gaudet,et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. , 2015, The New England journal of medicine.
[97] L. Niskanen,et al. Cross-linking of sodium caseinate-structured emulsion with transglutaminase alters postprandial metabolic and appetite responses in healthy young individuals , 2015, British Journal of Nutrition.
[98] L. Sidossis,et al. Physiology in Medicine: update on lifestyle determinants of postprandial triacylglycerolemia with emphasis on the Mediterranean lifestyle. , 2015, American journal of physiology. Endocrinology and metabolism.
[99] G. Watts,et al. Challenges in the treatment of hypertriglyceridemia: glass half empty or half full? , 2015, Expert review of clinical pharmacology.
[100] G. Lewis,et al. Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism , 2015, Diabetes.
[101] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[102] D. Mikhailidis,et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. , 2015, World journal of gastroenterology.
[103] Gerald F. Watts,et al. Effect of Dietary Fatty Acids on Human Lipoprotein Metabolism: A Comprehensive Update , 2015, Nutrients.
[104] A. Barker,et al. Exercise intensity and the protection from postprandial vascular dysfunction in adolescents. , 2015, American journal of physiology. Heart and circulatory physiology.
[105] Barry J. Davis,et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.
[106] Eric C. Freese,et al. Acute and chronic effects of sprint interval exercise on postprandial lipemia in women at-risk for the metabolic syndrome. , 2015, Journal of applied physiology.
[107] L. O’Driscoll,et al. Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. , 2015, The American journal of clinical nutrition.
[108] T. Vasankari,et al. Postprandial triglyceride response in normolipidemic, hyperlipidemic and obese subjects – the influence of polydextrose, a non-digestible carbohydrate , 2015, Nutrition Journal.
[109] G. Watts,et al. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. , 2015, Clinical science.
[110] B. Nordestgaard,et al. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. , 2015, Clinical chemistry.
[111] D. Gaudet,et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome , 2015, Lipids in Health and Disease.
[112] Anne Tybjærg-Hansen,et al. Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood Pressure as Mediators From Obesity to Ischemic Heart Disease , 2015, Circulation research.
[113] M. Nakata,et al. Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia , 2015, Lipids in Health and Disease.
[114] L. Scott. Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency , 2015, Drugs.
[115] D. Gaudet,et al. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. , 2014, Journal of the American College of Cardiology.
[116] G. Kolovou,et al. Severe/Extreme Hypertriglyceridemia and LDL Apheretic Treatment: Review of the Literature, Original Findings , 2014, Cholesterol.
[117] M. Taskinen,et al. Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia , 2014, BMC Endocrine Disorders.
[118] Hiroshi Ito,et al. Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals , 2014, Experimental and therapeutic medicine.
[119] A. Sahebkar. Circulating Levels of Proprotein Convertase Subtilisin Kexin Type 9 are Elevated by Fibrate Therapy: A Systematic Review and Meta-Analysis of Clinical Trials , 2014, Cardiology in review.
[120] J. Ordovás,et al. Metabolic phenotypes of obesity influence triglyceride and inflammation homoeostasis , 2014, European journal of clinical investigation.
[121] M. Hermann,et al. Postprandial lipemia induces pancreatic α cell dysfunction characteristic of type 2 diabetes: studies in healthy subjects, mouse pancreatic islets, and cultured pancreatic α cells. , 2014, The American journal of clinical nutrition.
[122] Hiroshi Ito,et al. Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[123] Jennifer G. Robinson,et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. , 2014, International journal of cardiology.
[124] Jefferson Petto,et al. Comparison of Postprandial Lipemia between Women who are on Oral Contraceptive Methods and Those who are not , 2014, Arquivos brasileiros de cardiologia.
[125] R. Giugliano,et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. , 2014, European heart journal.
[126] N. Patel,et al. Inhibitors of pancreatic lipase: state of the art and clinical perspectives , 2014, EXCLI journal.
[127] Anette Varbo,et al. Triglycerides and cardiovascular disease , 2014, The Lancet.
[128] W. Hall,et al. High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2α concentrations relative to a control high–oleic acid meal: a randomized controlled trial , 2014, The American journal of clinical nutrition.
[129] N. Katsilambros,et al. Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide , 2014, Journal of diabetes research.
[130] J. Borén,et al. Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride‐rich lipoproteins , 2014, Obesity.
[131] N. Samani,et al. Mendelian randomization studies in coronary artery disease. , 2014, European heart journal.
[132] J. Borén,et al. Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management , 2022 .
[133] He Zhang,et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.
[134] B. Nordestgaard,et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.
[135] A. D'Angelo,et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. , 2014, Metabolism: clinical and experimental.
[136] E. Plaisance,et al. Exercise and Dietary-Mediated Reductions in Postprandial Lipemia , 2014, Journal of nutrition and metabolism.
[137] H. Bays,et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.
[138] G Lippi,et al. Standardization of collection requirements for fasting samples: for the Working Group on Preanalytical Phase (WG-PA) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). , 2014, Clinica chimica acta; international journal of clinical chemistry.
[139] Jennifer G. Robinson,et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. , 2014, JAMA.
[140] C. Ballantyne,et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. , 2014, The New England journal of medicine.
[141] C. Katsanos. Clinical considerations and mechanistic determinants of postprandial lipemia in older adults. , 2014, Advances in nutrition.
[142] A. Kwakernaak,et al. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins. , 2014, Clinical biochemistry.
[143] A. Thackray,et al. Acute exercise and postprandial lipemia in young people. , 2014, Pediatric exercise science.
[144] B. Nordestgaard,et al. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. , 2014, Clinical chemistry.
[145] G. Nijpels,et al. SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus , 2014, Obesity.
[146] B. Capaldo,et al. Early Improvement of Postprandial Lipemia After Bariatric Surgery in Obese Type 2 Diabetic Patients , 2014, Obesity Surgery.
[147] Kohkichi Morimoto,et al. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice. , 2014, Endocrinology.
[148] J. Borén,et al. Postprandial hypertriglyceridemia as a coronary risk factor. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[149] H. Morita,et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study , 2014, Cardiovascular Diabetology.
[150] Eric C. Freese,et al. Effect of prior exercise on postprandial lipemia: an updated quantitative review (705.14) , 2014, Journal of applied physiology.
[151] G. Norata,et al. Postprandial lipemia as a cardiometabolic risk factor , 2014, Current medical research and opinion.
[152] S. Yamashita,et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[153] J. O’Connell,et al. Genome-wide association studies identified novel loci for non-high-density lipoprotein cholesterol and its postprandial lipemic response , 2014, Human Genetics.
[154] B. Nordestgaard,et al. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. , 2014, Pharmacology & therapeutics.
[155] R. Giacco,et al. Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial. , 2014, The American journal of clinical nutrition.
[156] G. Lewis,et al. Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans , 2014, Diabetes.
[157] B. C. Teixeira,et al. Resistance exercise at variable volume does not reduce postprandial lipemia in postmenopausal women , 2014, AGE.
[158] G. Kolovou,et al. Postprandial lipid profile in patients with type 2 diabetes , 2014, Current medical research and opinion.
[159] Huixia Lu,et al. Effects of the n-6/n-3 polyunsaturated fatty acids ratio on postprandial metabolism in hypertriacylglycerolemia patients , 2013, Lipids in Health and Disease.
[160] A. Pietraszek,et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial , 2013, Diabetes, obesity & metabolism.
[161] L. Aronne,et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2013, International Journal of Obesity.
[162] Tanya M. Teslovich,et al. Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.
[163] Tanya M. Teslovich,et al. Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.
[164] D. Ng. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. , 2013, Canadian journal of diabetes.
[165] L. Vatten,et al. Dairy products and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of cohort studies. , 2013, The American journal of clinical nutrition.
[166] Yoshiya Tanaka,et al. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes , 2013, Lipids in Health and Disease.
[167] M. Zanella,et al. Postprandial adiponectin levels are associated with improvements in postprandial triglycerides after Roux-en-Y gastric bypass in type 2 diabetic patients. , 2013, Metabolic syndrome and related disorders.
[168] B. Nordestgaard,et al. Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.
[169] V. Pīrāgs,et al. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects , 2013, Lipids in Health and Disease.
[170] A. Thackray,et al. Acute high-intensity interval running reduces postprandial lipemia in boys. , 2013, Medicine and science in sports and exercise.
[171] G. Ball,et al. A meal high in saturated fat evokes postprandial dyslipemia, hyperinsulinemia, and altered lipoprotein expression in obese children with and without nonalcoholic fatty liver disease. , 2013, JPEN. Journal of parenteral and enteral nutrition.
[172] B. Pillot,et al. Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1 , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[173] B. Nordestgaard,et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.
[174] Marc A. Tuazon,et al. Golem and resistance exercise metabolism in obese women after either endurance or Postprandial triglyceride and free fatty acid , 2013 .
[175] H. Roche,et al. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study , 2013, Experimental & Molecular Medicine.
[176] M. Taskinen,et al. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes , 2013, Diabetic medicine : a journal of the British Diabetic Association.
[177] B. Olmedilla-Alonso,et al. Composition of two Spanish common dry beans (Phaseolus vulgaris), 'Almonga' and 'Curruquilla', and their postprandial effect in type 2 diabetics. , 2013, Journal of the science of food and agriculture.
[178] J. Kuk,et al. Effects of acute exercise on postprandial triglyceride response after a high-fat meal in overweight black and white adolescents , 2013, International Journal of Obesity.
[179] Päivi Pajukanta,et al. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci , 2013, Journal of Medical Genetics.
[180] F. Tinahones,et al. Postprandial hypertriglyceridemia predicts improvement in insulin resistance in obese patients after bariatric surgery. , 2013, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.
[181] S. França,et al. The influence of weight excess on the postprandial lipemia in adolescents , 2013, Lipids in Health and Disease.
[182] S. Toubro,et al. Flaxseed dietary fibers suppress postprandial lipemia and appetite sensation in young men. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[183] G. Navis,et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. , 2013, Atherosclerosis.
[184] R. Segurado,et al. Within-person variation in the postprandial lipemic response of healthy adults. , 2013, The American journal of clinical nutrition.
[185] D. Bessesen,et al. The effects of sex, metabolic syndrome and exercise on postprandial lipemia. , 2013, Metabolism: clinical and experimental.
[186] B. Nordestgaard,et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.
[187] G. Watts,et al. Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies , 2013, Current Atherosclerosis Reports.
[188] H. Ginsberg,et al. Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial , 2013, Diabetes Care.
[189] H. Morita,et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report , 2013, Cardiovascular Diabetology.
[190] R. Kreis,et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets , 2013, Nutrition & Metabolism.
[191] H. Sinzinger,et al. Isoprostane normalisieren sich rasch nach Beendigung des Zigarettenrauchens bei gesunden Erwachsenen , 2013 .
[192] V. Gebski,et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. , 2012, JAMA.
[193] R. Giugliano,et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study , 2012, The Lancet.
[194] H. Naruse,et al. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. , 2012, Journal of cardiology.
[195] D. Rader,et al. Extended-release niacin acutely suppresses postprandial triglyceridemia. , 2012, The American journal of medicine.
[196] A. Garber. Postprandial dysmetabolism and the heart. , 2012, Heart failure clinics.
[197] M. Bahçeci,et al. Postprandial hyperlipidemia in overt and subclinical hypothyroidism. , 2012, European journal of internal medicine.
[198] F. Sacks,et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.
[199] K. Chinna,et al. Dietary Health Behaviors of Women Living in High Rise Dwellings: A Case Study of an Urban Community in Malaysia , 2012, Journal of Community Health.
[200] W. Weintraub,et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. , 2012, Atherosclerosis.
[201] G. Watts,et al. Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects , 2012, Current opinion in lipidology.
[202] J. Obata,et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. , 2012, Journal of cardiology.
[203] K. Adeli,et al. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. , 2012, American journal of physiology. Gastrointestinal and liver physiology.
[204] D. Waters,et al. Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study , 2012, Circulation.
[205] P. Pérez-Martínez,et al. Body mass interacts with fat quality to determine the postprandial lipoprotein response in healthy young adults. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[206] A. Zwinderman,et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. , 2012, JAMA.
[207] Y. Jang,et al. Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipedemia , 2012, Journal of cardiovascular pharmacology and therapeutics.
[208] A. James,et al. The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men , 2012, Nutrition & Metabolism.
[209] A. Branchi,et al. Changes in Serum Lipids and Blood Glucose in Non Diabetic Patients with Metabolic Syndrome after Mixed Meals of Different Composition , 2012, Journal of nutrition and metabolism.
[210] R. Badaró,et al. Obesity and postprandial lipemia in adolescents: risk factors for cardiovascular disease. , 2012, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.
[211] K. Gadde,et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.
[212] D. Panagiotakos,et al. Validity of abbreviated oral fat tolerance tests for assessing postprandial lipemia. , 2011, Clinical nutrition.
[213] Eric C. Freese,et al. Effects of acute sprint interval cycling and energy replacement on postprandial lipemia. , 2011, Journal of applied physiology.
[214] Tien-Hsiung Ku,et al. Genetic copy number variants in myocardial infarction patients with hyperlipidemia , 2011, BMC Genomics.
[215] G. Musso,et al. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.
[216] K. Kotani,et al. Effect of Ezetimibe on Remnant-Like Particle Cholesterol in Subjects with Metabolic Syndrome , 2011, Medical Principles and Practice.
[217] S. Woods,et al. Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. , 2011, Gastroenterology.
[218] K. Kelley,et al. Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β-cell response in subjects with primary hypertriglyceridemia. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.
[219] W. März,et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. , 2011, Current vascular pharmacology.
[220] H. Morita,et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. , 2011, Atherosclerosis.
[221] H. Scharnagl,et al. Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes. , 2011, European journal of endocrinology.
[222] N. Weissman,et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. , 2011, The Journal of clinical endocrinology and metabolism.
[223] G. Riccardi,et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. , 2011, Atherosclerosis.
[224] A. Nakashima,et al. Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[225] Moshe Levi,et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.
[226] P. Clifton,et al. Slowly and rapidly digested fat emulsions are equally satiating but their triglycerides are differentially absorbed and metabolized in humans. , 2011, The Journal of nutrition.
[227] B. Nordestgaard,et al. Methods to study postprandial lipemia. , 2011, Current vascular pharmacology.
[228] B. Nordestgaard,et al. Definition of postprandial lipaemia. , 2011, Current vascular pharmacology.
[229] D. Panagiotakos,et al. Lifestyle Intervention Leading to Moderate Weight Loss Normalizes Postprandial Triacylglycerolemia Despite Persisting Obesity , 2011, Obesity.
[230] P. Pérez-Martínez,et al. Nutrigenetics of the postprandial lipoprotein metabolism: evidences from human intervention studies. , 2011, Current vascular pharmacology.
[231] B. Nordestgaard,et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis , 2011 .
[232] H. Aburatani,et al. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. , 2011, Metabolism: clinical and experimental.
[233] B. Nordestgaard,et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. , 2011, Current vascular pharmacology.
[234] J. Borén,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.
[235] K. Gadde,et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[236] G. Kolovou,et al. Familial hypercholesterolemia and triglyceride metabolism. , 2011, International journal of cardiology.
[237] B. Nordestgaard,et al. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. , 2011, Clinical chemistry.
[238] D. Mikhailidis,et al. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? , 2011, Expert opinion on pharmacotherapy.
[239] S. Azar,et al. Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. , 2011, Molecular genetics and metabolism.
[240] Antonio Reverter,et al. Genome-wide patterns of promoter sharing and co-expression in bovine skeletal muscle , 2011, BMC Genomics.
[241] R. Rosenson,et al. Heterogeneous Postprandial Lipoprotein Responses in the Metabolic Syndrome, and Response to Fenofibrate Therapy , 2010, Cardiovascular Drugs and Therapy.
[242] G. Kolovou,et al. Postprandial metabolic heterogeneity in men with primary dyslipidaemia , 2010, Archives of medical science : AMS.
[243] L. Jia,et al. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis[S] , 2010, Journal of Lipid Research.
[244] M. Noakes,et al. The effect of modifying dietary protein and carbohydrate in weight loss on arterial compliance and postprandial lipidemia in overweight women with polycystic ovary syndrome. , 2010, Fertility and sterility.
[245] A. Saiki,et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients. , 2010, Journal of atherosclerosis and thrombosis.
[246] J. I. Pedersen,et al. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study , 2010, European Journal of Epidemiology.
[247] O. Yasuda,et al. Ezetimibe Ameliorates Cardiovascular Complications and Hepatic Steatosis in Obese and Type 2 Diabetic db/db Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.
[248] A. Wallace,et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. , 2010, The American journal of cardiology.
[249] S. Yamashita,et al. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. , 2010, Journal of atherosclerosis and thrombosis.
[250] P. Reaven,et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. , 2010, Atherosclerosis.
[251] M. Taskinen,et al. Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. , 2010, Atherosclerosis.
[252] P. Pérez-Martínez,et al. Update on genetics of postprandial lipemia. , 2010, Atherosclerosis. Supplements.
[253] Sonia S Anand,et al. Mendelian randomisation, triglycerides, and CHD , 2010, The Lancet.
[254] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[255] P. González-Sántos,et al. Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[256] G. Watts,et al. Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet , 2010, Diabetes Care.
[257] L. Berglund,et al. Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes Mellitus , 2010, Current diabetes reports.
[258] J. Ordovás,et al. Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men[S] , 2010, Journal of Lipid Research.
[259] G. Labbadia,et al. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. , 2009, Artificial organs.
[260] J. Danesh,et al. Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.
[261] A. Astrup,et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.
[262] N. Vaziri. Innovation in the Treatment of Uremia: Proceedings from the Cleveland Clinic Workshop: Causes of Dysregulation of Lipid Metabolism in Chronic Renal Failure , 2009, Seminars in dialysis.
[263] G. Kolovou,et al. Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs. , 2009, Current medicinal chemistry.
[264] S. Grundy,et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. , 2009, The American journal of cardiology.
[265] A. Astrup,et al. Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. , 2009, The American journal of clinical nutrition.
[266] G. Kolovou,et al. The Link Between Human and Transgenic Animal Studies Involving Postprandial Hypertriglyceridemia and CETP Gene Polymorphisms , 2009, The open cardiovascular medicine journal.
[267] M. Krempf,et al. Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[268] G. Rosenhamer,et al. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.
[269] I. Borecki,et al. Smoking, inflammatory patterns and postprandial hypertriglyceridemia. , 2009, Atherosclerosis.
[270] G. Kolovou,et al. Editorial [Hot Topic: One Century of Triglycerides, but there is Still Lots to Learn(Guest Editors: K. Anagnostopoulou, D.P. Mikhailidis and G. Kolovou)] , 2009 .
[271] G. Kolovou,et al. Primary and secondary hypertriglyceridaemia. , 2009, Current drug targets.
[272] L. Hilsted,et al. [Plasma lipids in non-fasting patients and signal values of laboratory results]. , 2009, Ugeskrift for laeger.
[273] D. Tanné,et al. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. , 2009, Archives of internal medicine.
[274] D. O'Gorman,et al. Influence of acute exercise with and without carbohydrate replacement on postprandial lipid metabolism. , 2009, Journal of applied physiology.
[275] R. Mattes. Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[276] J. O’Connell,et al. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.
[277] B. Nordestgaard,et al. Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.
[278] N. Katsilambros,et al. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. , 2008, Current diabetes reviews.
[279] A. Keech,et al. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.
[280] B. Nordestgaard,et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.
[281] J. Ordovás,et al. Influence of genetic factors in the modulation of postprandial lipemia. , 2008, Atherosclerosis. Supplements.
[282] R. Bloomer,et al. Postprandial oxidative stress is exacerbated in cigarette smokers , 2008, British Journal of Nutrition.
[283] A. Halpern,et al. Orlistat in the prevention of diabetes in the obese patient , 2008, Vascular health and risk management.
[284] R. Giacco,et al. Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. , 2008, Clinical nutrition.
[285] B. Kiens,et al. The effect of exercise on postprandial lipidemia in type 2 diabetic patients , 2007, European Journal of Applied Physiology.
[286] A. Gotto,et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.
[287] G. Kolovou,et al. Gender influence on postprandial lipemia in heterozygotes for familial hypercholesterolemia. , 2007, Annals of clinical and laboratory science.
[288] H. Koyama,et al. Clinical impact of metabolic syndrome by modified NCEP-ATPIII criteria on carotid atherosclerosis in Japanese adults. , 2007, Journal of atherosclerosis and thrombosis.
[289] B. Nordestgaard,et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.
[290] P. Ridker,et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.
[291] G. Kolovou,et al. The Prevalence of Metabolic Syndrome in Various Populations , 2007, The American journal of the medical sciences.
[292] S. Daskalopoulou,et al. The effect of statins on postprandial lipemia. , 2007, Current drug targets.
[293] H. Ginsberg,et al. Lipoprotein metabolism in chronic renal insufficiency , 2007, Pediatric Nephrology.
[294] J. Danesh,et al. Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.
[295] N. Katsilambros,et al. High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria Published, JLR Papers in Press, October 3, 2006. , 2007, Journal of Lipid Research.
[296] G. Kolovou,et al. Metabolic syndrome and gender differences in postprandial lipaemia , 2006 .
[297] G. Riccardi,et al. Atorvastatin or fenofibrate on post‐prandial lipaemia in type 2 diabetic patients with hyperlipidaemia , 2006, European journal of clinical investigation.
[298] G. Kolovou,et al. Alcohol Use, Vascular Disease, and Lipid-Lowering Drugs , 2006, Journal of Pharmacology and Experimental Therapeutics.
[299] P. Pérez-Martínez,et al. Postprandial lipoprotein metabolism, genes and risk of cardiovascular disease , 2006, Current opinion in lipidology.
[300] A. Häkkinen,et al. Overproduction of large VLDL particles is driven by increased liver fat content in man , 2006, Diabetologia.
[301] D. Panagiotakos,et al. Increase in aortic pulse wave velocity is associated with abnormal postprandial triglyceride response , 2005, Clinical cardiology.
[302] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[303] G. Pacini,et al. Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease , 2005, Hepatology.
[304] S. Daskalopoulou,et al. Clinical relevance of postprandial lipaemia. , 2005, Current medicinal chemistry.
[305] L. Campbell,et al. Insulin resistance and postprandial triglyceride levels in primary renal disease. , 2005, Metabolism: clinical and experimental.
[306] G. Kolovou,et al. Pathophysiology of dyslipidaemia in the metabolic syndrome , 2005, Postgraduate Medical Journal.
[307] J. Falko,et al. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia. , 2005, Current Diabetes Reviews.
[308] G. Kolovou,et al. The influence of natural menopause on postprandial lipemia in heterozygotes for familial hypercholesterolemia. , 2004, Journal of women's health.
[309] M. Castro Cabezas,et al. Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia. , 2004, The Journal of clinical endocrinology and metabolism.
[310] K. Olive,et al. Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. , 2004, The American journal of the medical sciences.
[311] G. Kolovou,et al. Heterozygote men with familial hypercholesterolaemia may have an abnormal triglyceride response post‐prandially. Evidence for another predictor of vascular risk in familial hypercholesterolaemia , 2004, International journal of clinical practice.
[312] Carolyn M Hutter,et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.
[313] W. Yancy,et al. A Low-Carbohydrate, Ketogenic Diet versus a Low-Fat Diet To Treat Obesity and Hyperlipidemia , 2004, Annals of Internal Medicine.
[314] A. Margeli,et al. The effect of alcohol and gemfibrozil co-administration in Wistar rats. , 2004, In vivo.
[315] G. Kolovou,et al. The effect of co-administration of simvastatin and alcohol in rats. , 2003, In vivo.
[316] J. Brunzell,et al. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. , 2003, The American journal of cardiology.
[317] P. Macfarlane,et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.
[318] G. Watts,et al. Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. , 2003, Clinical science.
[319] G. Musso,et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.
[320] J. Holst,et al. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. , 2003, The American journal of clinical nutrition.
[321] G. Watts,et al. Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. , 2003, Metabolism: clinical and experimental.
[322] D. Bessesen,et al. Postprandial leg uptake of triglyceride is greater in women than in men. , 2002, American journal of physiology. Endocrinology and metabolism.
[323] S. Mochizuki,et al. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. , 2002, Metabolism: clinical and experimental.
[324] B. Föger,et al. Insulin improves fasting and postprandial lipemia in type 2 diabetes. , 2002, European journal of internal medicine.
[325] B. Kiens,et al. Myocellular triacylglycerol breakdown in females but not in males during exercise. , 2002, American journal of physiology. Endocrinology and metabolism.
[326] J. Ribalta,et al. A proposal to redefine familial combined hyperlipidaemia – Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation , 2002, European journal of clinical investigation.
[327] E. Levy,et al. Determinants of Lipid Level Variability in French-Canadian Children With Familial Hypercholesterolemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[328] G. Watts,et al. Elevated apolipoprotein B‐48 and remnant‐like particle–cholesterol in heterozygous familial hypercholesterolaemia , 2001, European journal of clinical investigation.
[329] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[330] H. Gylling,et al. Introducing a new component of the metabolic syndrome: low cholesterol absorption. , 2000, The American journal of clinical nutrition.
[331] D. Erkelens,et al. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. , 2000, Journal of lipid research.
[332] B. Palumbo,et al. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. , 2000, VASA. Zeitschrift fur Gefasskrankheiten.
[333] A. Attie,et al. The role of the LDL receptor in apolipoprotein B secretion. , 2000, The Journal of clinical investigation.
[334] E. Rimm,et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors , 1999, BMJ.
[335] C. Bouchard,et al. Gender difference in postprandial lipemia : importance of visceral adipose tissue accumulation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[336] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[337] B. Nordestgaard,et al. Lipoprotein Lipase Mutations, Plasma Lipids and Lipoproteins, and Risk of Ischemic Heart Disease A Meta-Analysis , 1999 .
[338] H. Burger. The endocrinology of the menopauseProceedings of Xth International Congress on Hormonal Steroids, Quebec, Canada, 17–21 June 1998. , 1999, The Journal of Steroid Biochemistry and Molecular Biology.
[339] A. Levey. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[340] T. D. de Bruin,et al. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia , 1998, Journal of internal medicine.
[341] A. Hardman,et al. Postprandial lipemia in endurance-trained people during a short interruption to training. , 1998, Journal of applied physiology.
[342] Yu,et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia , 1998, European journal of clinical investigation.
[343] S. Andréasson. Alcohol and J-shaped curves. , 1998, Alcoholism, clinical and experimental research.
[344] M. Taskinen,et al. Postprandial elevation of ApoB-48-containing triglyceride-rich particles and retinyl esters in normolipemic males who smoke. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[345] G. Jensen,et al. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. , 1997, Circulation.
[346] R. Guerciolini. Mode of action of orlistat. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[347] P. Schnohr,et al. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. , 1997, The Journal of clinical investigation.
[348] M. Taskinen,et al. The insulin resistance syndrome and postprandial lipid intolerance in smokers. , 1997, Atherosclerosis.
[349] A. Hardman,et al. Acute effects of exercise on postprandial lipemia: a comparative study in trained and untrained middle-aged women. , 1997, The American journal of clinical nutrition.
[350] R. Krauss,et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.
[351] G. Coetzee,et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations , 1996, Human Genetics.
[352] J. Zhi,et al. Review of Limited Systemic Absorption of Orlistat, a Lipase Inhibitor, in Healthy Human Volunteers , 1995, Journal of clinical pharmacology.
[353] B. Gould,et al. Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role of lipoprotein lipase? , 1995, European journal of clinical nutrition.
[354] M. Taskinen,et al. Lipid intolerance in smokers , 1995, Journal of internal medicine.
[355] R. Wootton,et al. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[356] E. Johnson,et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. , 1993, Journal of lipid research.
[357] R. Havel,et al. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[358] Y. Ringel,et al. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. , 1992, Kidney international.
[359] A. Dattilo,et al. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.
[360] R. Wootton,et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[361] G. Coetzee,et al. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. , 1990, The Journal of clinical investigation.
[362] T. Jenkins,et al. Prevalence of familial hypercholesterolemia in Johannesburg Jews. , 1989, American journal of medical genetics.
[363] M. Lambert,et al. Homozygous Familial Hypercholesterolemia among French Canadians in Quebec Province , 1989, Arteriosclerosis.
[364] J. Huttunen,et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.
[365] R. Mahley,et al. Lipoprotein receptors and cholesterol homeostasis. , 1983, Biochimica et biophysica acta.
[366] A. Soutar,et al. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia. , 1982, Atherosclerosis.
[367] D. B. Zilversmit. Atherogenesis: a postprandial phenomenon. , 1979, Circulation.
[368] D. Galton,et al. TREATMENT OF SEVERE DIABETIC HYPERTRIGLYCERIDÆMIA BY PLASMA EXCHANGE , 1978, The Lancet.
[369] B. Shen,et al. Structure of human serum lipoproteins inferred from compositional analysis. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[370] S. Larsson,et al. The ground substance of the arterial wall. Part 1. Extractability of glycosaminoglycans and the isolation of a proteoglycan from bovine aorta. , 1975, Atherosclerosis.
[371] G. Reaven,et al. Moderate ethanol ingestion and plasma triglyceride levels. A study in normal and hypertriglyceridemic persons. , 1974, Annals of internal medicine.
[372] G. Watts,et al. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement , 2019, Current vascular pharmacology.
[373] B. Nordestgaard,et al. Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. , 2018, Clinical chemistry.
[374] A. Hoes,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.
[375] W. Brown. From the Editor: Cytokines and HDL cholesterol. Foreword. , 2015, Journal of clinical lipidology.
[376] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[377] J. Rutledge,et al. Postprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFκB. , 2014, American journal of physiology. Heart and circulatory physiology.
[378] G. Costabile,et al. A CHO/fibre diet reduces and a MUFA diet increases postprandial lipaemia in type 2 diabetes: no supplementary effects of low-volume physical training , 2013, Acta Diabetologica.
[379] M. Naito,et al. Acute effects of postprandial aerobic exercise on glucose and lipoprotein metabolism in healthy young women. , 2013, Journal of atherosclerosis and thrombosis.
[380] F. Tinahones,et al. Lipid metabolism after an oral fat test meal is affected by age-associated features of metabolic syndrome, but not by age. , 2013, Atherosclerosis.
[381] D. Lairon,et al. Modulating absorption and postprandial handling of dietary fatty acids by structuring fat in the meal: a randomized crossover clinical trial. , 2013, The American journal of clinical nutrition.
[382] Jennifer G. Robinson,et al. Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.
[383] A. Minihane,et al. Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. , 2012, Atherosclerosis.
[384] A. Minihane,et al. A sequential two meal challenge reveals abnormalities in postprandial TAG but not glucose in men with increasing numbers of metabolic syndrome components. , 2012, Atherosclerosis.
[385] M. Nakazato,et al. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. , 2012, Journal of atherosclerosis and thrombosis.
[386] G. Watts,et al. Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. , 2012, Metabolism: clinical and experimental.
[387] L. Mercado-Asis,et al. Postprandial Effect of Orlistat on the Peaking of Lipid Level After Sequential High Fat Meals , 2012, International journal of endocrinology and metabolism.
[388] Y. Terauchi,et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. , 2012, Journal of atherosclerosis and thrombosis.
[389] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.
[390] Y. Terauchi,et al. Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. , 2012, Journal of atherosclerosis and thrombosis.
[391] Chie Aoki,et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. , 2011, Endocrine journal.
[392] B. Abramson,et al. Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients , 2011, Lipids in Health and Disease.
[393] J. Danesh,et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.
[394] T. Okanoue,et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease , 2010, Journal of Gastroenterology.
[395] N. Tentolouris,et al. The effects of medications used for the management of dyslipidemia on postprandial lipemia. , 2009, Current medicinal chemistry.
[396] D. O'Neal,et al. Lipids in Health and Disease , 2009 .
[397] G. Kolovou,et al. Therapeutic Effects of Fibrates in Postprandial Lipemia , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[398] S. Grundy. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. , 2006, Clinical cornerstone.
[399] E. Parks,et al. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. , 2005, The American journal of clinical nutrition.
[400] G. Kolovou,et al. The effect of nicotinic acid and alcohol co-administration in Wistar rats. , 2005, Methods and findings in experimental and clinical pharmacology.
[401] A. Hoes,et al. [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.
[402] R. Holman,et al. A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test. , 2004, Diabetes care.
[403] C. Lieber,et al. Relationships Between Nutrition, Alcohol Use, and Liver Disease , 2003, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.
[404] F. Ohsuzu,et al. Effect of a low-fat diet enriched with oleic acid on postprandial lipemia in patients with type 2 diabetes mellitus , 2001, Lipids.
[405] F. Berthou,et al. Cytochrome P-450 2E1 activity and oxidative stress in alcoholic patients. , 2000, Alcohol and alcoholism.
[406] B. Nordestgaard,et al. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.